Stichting Dienst Landbouwkundig Onderzoek

Plant Research International B.v.

Isobionics B.v.

Novartis Ag

Syngenta Participations Ag

Sandoz Gmbh

Axxence Aromatic Gmbh

Stichting Dienst Landbouwkundig Onderzock

Hendrik Jan Bosch

Hendrikus Antonius Cornelis Bakker

Dionisius Elisabeth Antonius Florack

Gerard Johan Adolph Rouwendal

Willem Johannes Stiekema

Martinus Julius Beekwilder

Georg Friedrich Lentzen

Adèle Margaretha Maria Liduina Van Houwelingen

Elena Melillo

Theodorus Sonke

Hendrik Wouter Wisselink

Maarten Anthonie Jongsma

Vito Turk

Borut Strukelj

Hendrik Jan Bouwmeester

Kristina Gruden

Brigita Lenarcic

Jihane Achkar

Wilhelmina Maria Johanna Weemen

Peter Hans Van Der Schaft

Katarina Cankar

Hendrikus Antonius Cornelus Bakker

Hendrikus Antonius Cornelius Bakker

The invention is directed to a patchoulol synthase, to a nucleic acid encoding said patchoulol synthase, to an expression vector comprising said nucleic acid, to a host cell comprising said expression vector, to a method of preparing patchoulol and elemol, and preferably also pogostol, and to a method of preparing a patchoulol synthase.

Terpene synthase producing patchoulol and elemol, and preferably also pogostol

The invention is directed to a santalene synthase, to a nucleic acid encoding said santalene synthase, to an expression vector comprising said nucleic acid, to a host cell comprising said expression vector, to a method of preparing santalene, to a method of preparing santalol and to a method of preparing a santalene synthase. The invention is further directed to an antibody specific for the santalane synthase.

Santalene synthase

The present invention relates to the field of biotechnology; specifically the production of a flavor compound (raspberry ketone) in a host cell.

Production of a flavour compound in a host cell

The present invention relates to non-mammalian &#x3b2;-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian &#x3b2;-1,4-galactosyltransferases and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation. The invention additionally provides nucleic acid molecules and expression vectors of non-mammalian &#x3b2;-1,4-galactosyltransferases.

Mammalian-type glycosylation in plants by expression of a zebrafish glycosyltransferase

The present invention relates to a valencene synthase, to a nucleic acid encoding such valencene synthase, to a host cell comprising said encoding nucleic acid sequence and to a method for preparing valencene, comprising converting farnesyl diphosphate to valencene in the presence of a valencene synthase according to the invention.

Valencene synthase from callitropsis nootkatensis

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

GNTIII expression in plants

The invention is directed to methods for optimizing glycan processing in organisms (and in particular, plants) so that a glycoprotein having complex type bi-antennary glycans and thus containing galactose residues on both arms and which are devoid of (or reduce in) xylose and fucose can be obtained. The invention is further directed to said glycoprotein obtained and host system comprising said protein.

Optimizing glycan processing in plants

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides a plant comprising functional mammalian &#x3b2;1,4-galactosyltransferase and mammalian sialyl transferase for producing complex N-linked glycans that are galactosylated and sialylated, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Transgenic plants expressing galactosyltransferase and sialyl transferase

The present invention relates to non-mammalian &#x3b2;-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian &#x3b2;-1,4-galactosyltransferase and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation. The invention additionally provides nucleic acid molecules and expression vectors of non-mammalian &#x3b2;-1,4-galactosyltransferases.

Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides a plant comprising a functional mammalian enzyme providing N-glycan biosynthesis that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Plant expressing mammalian &#x3b2;1,4-galactosyltransferase and &#x3b2;1,3-glucuronyltransferase

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants. 

GnTIII expression in plants

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides plants and plant cells comprising of functional mammalian enzyme providing N-glycan biosynthesis that is normally not present in plants, for example mammalian &#x3b2; 1,4-galactosyltransferase, said plants or plant cells additionally comprising at least a second mammalian protein or functional fragment thereof, for example a mammalian antibody, that is normally not present in plants.

Mammalian-type glycosylation in transgenic plants expressing mammalian &#x3b2;1,4-galactosyltransferase

The invention is directed to methods for optimizing glycan processing in organisms (and in particular, plants) so that a glycoprotein having complex type bi-antennary glycans and thus 5 containing galactose residues on both arms and which are devoid of (or reduce in) xylose and fucose can be obtained. The invention is further directed to said glycoprotein obtained and host system comprising said protein.

Growing community of inventors

Wageningen, Netherlands

Hendrik Jan Bosch